Skip to main content

Advertisement

Table 1 Patient characteristics

From: Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation

Variables N (%) Low NLR (%) High NLR(%) P-value
Gender     
Female 50 (25.1) 35 (70.0) 15 (30.0)  
Male 149 (74.9) 98 (65.8) 51 (34.2) 0.583
Age, years     
<60 135 (67.2) 90 (66.7) 45 (33.3)  
≥60 64 (31.8) 43 (67.2) 21 (32.8) 0.942
Tumor stage before CRT    
II 26 (13.1) 23 (88.5) 3 (11.5)  
III 173 (86.9) 110 (63.6) 63 (36.4) 0.012
Tumor location     
Low 122 (61.3) 82 (67.2) 40 (32.8)  
Middle-high 77 (38.7) 51 (66.2) 26 (33.8) 0.886
CEA, ng/ml     
<5 110 (55.3) 77 (70.0) 33 (30.0)  
≥5 89 (44.7) 56 (62.9) 33 (37.1) 0.292
RT dose, Gy     
45-50 122 (61.3) 76 (62.3) 46 (37.7)  
>50 77 (38.7) 57 (74.0) 20 (26.0) 0.087
Surgical procedure     
APR 115 (57.8) 81 (70.4) 34 (29.6)  
LAR 70 (35.2) 45 (64.3) 25 (35.7)  
Hartmann 14 (7.0) 7 (50.0) 7 (50.0) 0.246*
ypTNM staging     
ypT0-2 N0 88 (44.2) 62 (70.5) 26 (29.5)  
ypT3-4 or N+ 111 (55.8) 71 (64.0) 40 (36.0) 0.334
TRG score     
0-1 117 (58.8) 82 (70.1) 35 (29.9)  
2-3 82 (41.2) 51 (62.2) 31 (37.8) 0.245
Adjuvant chemotherapy    
Yes 184 (92.5) 121 (65.8) 63 (34.2)  
No 15 (7.5) 12 (80.0) 3 (20.0) 0.393*
  1. (*Fisher’s exact test).